Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged
NEW YORK, Aug. 25, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ: SYRS). Investors who purchased Syros securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SYRS.
紐約，2024年8月25日 / PRNewswire / - 律師廣告 - Bronstein，Gewirtz＆Grossman，LLC正在調查有關Syros Pharmaceuticals，Inc.（"Syros"或"the Company"）（納斯達克：SYRS）購買者的潛在索賠。鼓勵購買Syros證券的投資者獲得額外信息，並通過訪問該公司的網站：bgandg.com/SYRS提供協助調查。
Investigation Details
調查詳情
On August 12, 2024, Syros issued a press release "announcing that it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial evaluating the triplet regimen of tamibarotene in combination with venetoclax and azacitidine compared to the doublet regimen of venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML) and RARA gene overexpression." According to the Company, the "decision is based on the results of a prespecified interim analysis of the trial," and its analysis that "the probability for success . . . to demonstrate superiority at the final analysis . . . was considered low."
2024年8月12日，Syros發表了一項新聞稿，"宣佈將停止在新診斷不適合的急性髓性白血病（AML）和RARA基因過度表達的患者中，評估tamibarotene與venetoclax和azacitidine的三聯方案與venetoclax和azacitidine的雙聯方案。根據該公司稱，"這個決定基於對試驗的預先指定的中期分析結果，並分析認爲"在最終分析中，表現出優勢的概率被認爲較低"。
What's Next?
下一步是什麼？
If you are aware of any facts relating to this investigation or purchased Syros securities, you can assist this investigation by visiting the firm's site: bgandg.com/SYRS. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
如果您了解與此調查相關的任何事實或購買了Syros證券，您可以通過訪問該公司的網站bgandg.com/SYRS來協助此項調查。您還可以聯繫Bronstein，Gewirtz＆Grossman，LLC的Peretz Bronstein或其客戶關係經理Nathan Miller：332-239-2660。
There is No Cost to You
您不需要支付任何費用
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
我們代表投資者進行集體訴訟，按照訴訟結果收取費用基礎。這意味着我們將要求法院償還我們的實際支出和律師費，通常是總賠償的一定比例，僅在我們成功時。
Why Bronstein, Gewirtz & Grossman
爲什麼選擇Bronstein，Gewirtz＆Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Bronstein，Gewirtz和Grossman，LLC是一家國際知名的公司，代表投資者進行證券欺詐集體訴訟和股東衍生訴訟。我們的公司已經爲全國投資者贏回了數億美元。
Attorney advertising. Prior results do not guarantee similar outcomes.
律師廣告。以前的結果不能保證相似的結果。
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | [email protected]
聯繫人
Bronstein，Gewirtz＆Grossman，LLC
Peretz Bronstein或Nathan Miller
332-239-2660 | [email protected]
SOURCE Bronstein, Gewirtz & Grossman, LLC
資料來源：Bronstein，Gewirtz＆Grossman，LLC
譯文內容由第三人軟體翻譯。